Condition: Prostate Cancer · Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
To determine if fBT+sRT is superior to standard care in terms of urinary toxicity by having fewer patients experience a minimal important decline (MID) in urinary irritation/obstructive QoL
This description comes directly from the study's public registry record.
Mom Phat · 514-890-8254 · mom.phat.chum@ssss.gouv.qc.ca
Always discuss trial participation with your own doctor first.
| Centre Hospitalier de l'Université de Montréal | Montreal, Quebec, Canada | Recruiting |
| CHUQ | Québec, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04100174